- Home
- SWKS vs AXSM Comparison
SWKS vs AXSM Comparison
Compare SWKS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SWKS | AXSM |
|---|---|---|
| Founded | 1962 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 8.6B |
| IPO Year | 1995 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SWKS | AXSM |
|---|---|---|
| Price | $57.19 | $183.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 17 |
| Target Price | $72.85 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 2.7M | 496.8K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 5.03% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $4,086,900,000.00 | N/A |
| Revenue This Year | N/A | $58.18 |
| Revenue Next Year | $3.06 | $55.45 |
| P/E Ratio | $106.53 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $51.93 | $96.09 |
| 52 Week High | $90.90 | $191.50 |
Technical Indicators
Market Signals| Indicator | SWKS | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 56.40 | 67.61 |
| Support Level | $56.52 | $178.00 |
| Resistance Level | $61.80 | $188.89 |
| Average True Range (ATR) | 1.72 | 6.13 |
| MACD | 0.47 | 2.44 |
| Stochastic Oscillator | 92.68 | 98.90 |
Price Performance
Historical ComparisonAbout SWKS Skyworks Solutions Inc.
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.